查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1146280

马来西亚糖尿病治疗设备市场 - 增长、趋势、COVID-19 的影响和预测 (2022-2027)

Malaysia Diabetes Care Devices Market - Growth, Trends, and Forecasts (2022 - 2027)
出版日期: | 出版商: Mordor Intelligence | 英文 70 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

在 2022 年至 2027 年的预测期内，马来西亚的糖尿病治疗设备市场预计将以超过 5.1% 的复合年增长率增长。

马来西亚卫生部表示，这个东南亚国家在 24 小时内记录了 5,809 例新的 COVID-19 病例，其中 5,782 例是国内感染，27 例是进口感染，使全国总数达到 2,541,147 例。宣布这是到目前为止，大约 78.4% 的马来西亚人已经接种了至少一剂针对 COVID-19 的疫苗，而 75.9% 的人已完全接种疫苗。卫生部告诉《星期日星报》，今年马来西亚 10 例 COVID-19 死亡病例中约有 4 例患有糖尿病。在马来西亚，五分之一的人患有糖尿病，约有 390 万 18 岁及以上的人患有糖尿病。

年轻糖尿病患者的数量正在增加。越来越多的年轻人患上糖尿病，在过去 15 年中，18 至 40 岁的人数翻了一番。越来越多的糖尿病患者意味着疾病及其并发症的负担越来越重，例如心脏病、中风、失明、慢性肾病和下肢截肢。

其实，大马死于新冠肺炎的，大部分都患有糖尿病、高血压等基础疾病，而且数字很高。

主要市场趋势

在马来西亚糖尿病治疗器械市场，管理器械占有较高的市场份额

马来西亚是西太平洋地区糖尿病患病率最高的国家，也是世界上糖尿病患病率最高的国家之一，每年的医疗保健费用约为 6 亿美元。这种上升趋势是由多种因素造成的，包括人口增长、人口老龄化、城市化以及肥胖率和缺乏运动率的上升。本研究的目的是系统地掌握马来西亚糖尿病和糖尿病前期的患病率，明确其特征，并进行估计。胰岛素泵的使用在西方急剧增加，尤其是在 1 型糖尿病患者中，但它在马来西亚的使用仍然非常有限。基础胰岛素注射取代了中效和长效皮下胰岛素注射，以预设的速率全天持续提供胰岛素，该速率可根据个人的具体要求进行修改。

这是一项由阿斯利康与马来西亚内分泌和代谢学会 (MEMS) 合作支持的社区倡议，这项初步调查将于 2021 年 4 月 12 日至 5 月 9 日在多家药房和媒体合作伙伴的支持下进行。在线日期。这项初步调查的目的是获得马来西亚意识水平的基线，并确定关键的知识差距。从今年的 2,539 份回復中得出的见解将决定阿斯利康和 MEMS 在来年如何塑造他们的公共教育工作。

政府在预测期内推动市场的举措。

马来西亚糖尿病患者人数上升

由于糖尿病和糖尿病前期在马来西亚呈上升趋势，马来西亚政府实施了一项全国性的糖尿病预防和控制计划。马来西亚政府应制定全面的方法和计划来提高糖尿病知识、控制、预防和治疗，以降低该国的糖尿病患病率。最近的一项 NHMS 发现，马来西亚有二分之一的成年人超重或肥胖。糖尿病患者血液中的葡萄糖和糖含量很高。糖尿病是一种当身体不能产生足够的激素胰岛素来控制血糖水平时发生的疾病。当身体不能有效使用胰岛素时，也可能发生这种情况，也称为胰岛素抵抗。推动这一过程的因素包括肥胖、不健康的饮食习惯、久坐的生活方式和遗传。在马来西亚，该部国家糖尿病登记处（NDR）的统计数据显示，84% 的糖尿病患者超重，其中大多数是 18 至 40 岁的年轻马来西亚人。该部目前正在考虑一项名为“Sama-Sama 计划”的倡议。它旨在帮助糖尿病患者的家人和护理人员提供支持并改善糖尿病控制和预后。 “在这个项目中，该部正在与私营部门合作培训医疗保健提供者和护理人员。在这个项目中，该部与私营公司合作培养卫生工作者，从而培养护理人员，以增强和提供支持，以改善疾病控制和结果.

因此，马来西亚的糖尿病治疗设备市场预计将在未来几年逐渐扩大。

竞争格局

连续血糖监测等糖尿病护理设备中的新技术扩大了监测设备的市场。参与者之间的併购，例如 Dexcom 收购 TypeZero Technologies，正在为胰岛素自动给药舖平道路。通过此次收购，Dexcom 不仅将推动血糖连续监测设备市场的发展，还将引领人工胰腺系统的研发竞赛。

其他好处

  • Excel 格式的市场预测 (ME) 表
  • 三个月的分析师支持

内容

第一章介绍

  • 研究假设和市场定义
  • 调查范围

第二章研究方法论

第 3 章执行摘要

第四章市场动态

  • 市场概览
  • 市场驱动因素
  • 市场製约因素
  • 产业吸引力 - 波特五力分析
    • 新进入者的威胁
    • 买方/消费者议价能力
    • 供应商的议价能力
    • 替代品的威胁
    • 竞争公司之间的敌对关係

第 5 章市场细分

  • 监控设备
    • 自我血糖监测设备（价值和数量，2016-2027 年）
      • 血糖仪设备
      • 试纸
      • 柳叶刀
    • 连续血糖监测（价值和数量，2016-2027 年）
      • 传感器
      • 耐用品
  • 託管设备
    • 胰岛素泵（价值和数量，2016-2027 年）
      • 胰岛素泵装置
      • 胰岛素泵储液器
      • 输液器
    • 胰岛素注射器（价值和数量，2016-2027 年）
    • 胰岛素药筒（价值和数量，2016-2027 年）
    • 一次性笔（价格和数量，2016-2027 年）

第六章市场指标

  • 1 型糖尿病人口（2016-2027 年）
  • 2 型糖尿病人口（2016-2027 年）

第七章竞争格局

  • 公司简介
    • Becton and Dickenson
    • Medtronic
    • Insulet
    • Tandem
    • Ypsomed
    • Novo Nordisk
    • Sanofi
    • Eli Lilly
    • Abbottt
    • Roche
    • Lifescan（Johnson &Johnson）
    • Dexcom
  • 企业占有率分析

第8章 市场机会与未来趋势

简介目录
Product Code: 91784

The Malaysia Diabetes Care Devices Market is expected to register a CAGR greater than 5.1% over the forecast period, 2022-2027.

The Malaysian Ministry of Health announced that the Southeast Asian nation recorded 5,809 new COVID-19 cases in 24 hours, including 5,782 domestically infected and 27 imported ones, bringing the national tally to 2,541,147. So far, about 78.4 percent of the Malaysian population have received at least one dose of vaccine against COVID-19, while 75.9 percent have been fully vaccinated. Out of every 10 people who died from COVID-19 in Malaysia this year, about four of them had diabetes, the Health Ministry tells Sunday Star. In Malaysia, one in five people lives with diabetes which works out to about 3.9 million people aged 18 and above.

Young diabetics are on the rise. A higher number of younger people are getting diabetes, with the number of patients aged between 18 and 40 doubling over the past 15 years. The rising number of diabetics means an increased burden of the disease and its complications: heart disease, stroke, blindness, chronic kidney disease, and lower limb amputation, among others.

In fact, most of the coronavirus deaths in Malaysia have underlying comorbidities, with diabetes and hypertension topping the list.

Key Market Trends

Management Devices Hold Highest Market Share in Malaysia Diabetes Care Devices Market

Malaysia has the highest rate of diabetes in the Western Pacific region and one of the highest in the world and costing around 600 million US dollars per year. The rising trend is due to several factors, including population growth, population aging, urbanization, and rising obesity and physical inactivity rates. The rising incidence of diabetes and its consequences in Malaysia inspired this study to systematically identify, characterize, and estimate the pooled prevalence of diabetes and prediabetes in Malaysia. Although the use of insulin pumps in the West has increased by leaps and bounds, especially among type 1 diabetic individuals, its use in Malaysia remains very limited. The basal insulin infusion, which substitutes the intermediate- or long-acting subcutaneous insulin injection, provides insulin continuously throughout the day at pre-set rates that are changed based on the individual's specific requirements.

A community initiative supported by AstraZeneca in partnership with the Malaysian Endocrine & Metabolic Society (MEMS), The first-ever survey took place online from 12 April until 9 May 2021, with the support of several pharmacies and media partners. The purpose of this inaugural survey is to obtain a baseline of Malaysia's awareness level and also to identify key knowledge gaps. The insights from this year's 2,539 responses (which have been stratified to represent the overall population) will shape the way AstraZeneca and MEMS conceptualises public education initiatives in the year ahead.

The Goverenment intiatives driving the market in forecast period.

Increasing Diabetes Population in Malaysia

Because diabetes and prediabetes are on the rise in Malaysia, the Malaysian government implements diabetes prevention and control programs across the country. The Malaysian government should establish a comprehensive approach and plan to improve diabetes knowledge, control, prevention, and treatment to reduce the prevalence of diabetes in the country. Being overweight and obese are key drivers of the younger diabetes population in Malaysia. recent NHMS found that one in two adults in Malaysia is overweight or obese. Those with diabetes have high levels of glucose or sugar in their blood. It's a disease that is caused by the body not producing enough of the hormone insulin to control the amount of blood sugar. It can also be caused when the body doesn't use insulin efficiently, also known as insulin resistance. Factors that drive this process include obesity, unhealthy eating habits, sedentary lifestyles, and genetics. In Malaysia, current statistics from the ministry's National Diabetes Registry (NDR)show that 84% of patients with diabetes are overweight, and among them are young Malaysians aged 18 to 40. The ministry is currently looking into an initiative known as the Sama-Sama program, which aims to empower family members and caregivers to provide support for people living with diabetes to improve control and outcomes of the disease. "Under the program, the ministry is joining forces with the private sector to train healthcare providers and later, caregivers. The ministry is now investigating the Sama-Sama program, which aims to empower family members and caregivers to offer support for persons living with diabetes to enhance disease control and outcomes. The ministry is collaborating with the commercial sector on the program to train healthcare personnel and, subsequently, carers.

As a result, the diabetes care devices market in Malaysia is predicted to expand gradually in the coming years.

Competitive Landscape

The new technologies in diabetes devices, like continuous glucose monitoring, increased the market for monitoring devices. The mergers and acquisitions between the players, like the acquisition of TypeZero Technologies by Dexcom, are paving the way for automated insulin delivery. The acquisition has sent Dexcom ahead on its way in the race to create an artificial pancreas system, rather than merely offering a boost to the continuous glucose monitoring devices market.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
  • 4.3 Market Restraints
  • 4.4 Industry Attractiveness - Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 Monitoring Devices
    • 5.1.1 Self-monitoring Blood Glucose Devices (Value and Volume, 2016 - 2027)
      • 5.1.1.1 Glucometer Devices
      • 5.1.1.2 Test Strips
      • 5.1.1.3 Lancets
    • 5.1.2 Continuous Blood Glucose Monitoring (Value and Volume, 2016 - 2027)
      • 5.1.2.1 Sensors
      • 5.1.2.2 Durables
  • 5.2 Management Devices
    • 5.2.1 Insulin Pump (Value and Volume, 2016 - 2027)
      • 5.2.1.1 Insulin Pump Device
      • 5.2.1.2 Insulin Pump Reservoir
      • 5.2.1.3 Infusion Set
    • 5.2.2 Insulin Syringes (Value and Volume, 2016 - 2027)
    • 5.2.3 Insulin Cartridges (Value and Volume, 2016 - 2027)
    • 5.2.4 Disposable Pens (Value and Volume, 2016 - 2027)

6 MARKET INDICATORS

  • 6.1 Type-1 Diabetes population (2016-2027)
  • 6.2 Type-2 Diabetes population (2016-2027)

7 COMPETITIVE LANDSCAPE

  • 7.1 Company Profiles
    • 7.1.1 Becton and Dickenson
    • 7.1.2 Medtronic
    • 7.1.3 Insulet
    • 7.1.4 Tandem
    • 7.1.5 Ypsomed
    • 7.1.6 Novo Nordisk
    • 7.1.7 Sanofi
    • 7.1.8 Eli Lilly
    • 7.1.9 Abbottt
    • 7.1.10 Roche
    • 7.1.11 Lifescan (Johnson &Johnson)
    • 7.1.12 Dexcom
  • 7.2 Company Share Analysis

8 MARKET OPPORTUNITIES AND FUTURE TRENDS